 | Up a level |
Peyvandi, F; Scully, M; Kremer Hovinga, Johanna Anna; Knöbl, P; Cataland, S; De Beuf, K; Callewaert, F; De Winter, H; Zeldin, R K (2017). Caplacizumab reduces the frequency of major thromboembolic events, exacerbations, and death in patients with acquired thrombotic thrombocytopenic purpura. Journal of thrombosis and haemostasis, 15(7), pp. 1448-1452. Wiley-Blackwell 10.1111/jth.13716
Plaimauer, B; Kremer Hovinga, J A; Juno, C; Wolfsegger, M J; Skalicky, S; Schmidt, M; Grillberger, L; Hasslacher, M; Knöbl, P; Ehrlich, H; Scheiflinger, F (2011). Recombinant ADAMTS13 normalizes von Willebrand factor-cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies. Journal of thrombosis and haemostasis, 9(5), pp. 936-44. Oxford: Wiley-Blackwell 10.1111/j.1538-7836.2011.04224.x
Tiede, A; Huth-Kühne, A; Oldenburg, J; Grossmann, R; Geisen, U; Krause, M; Brand, B; Alberio, L; Klamroth, R; Spannagl, M; Knöbl, P (2008). Erhebung zur immunsuppressiven Therapie der erworbenen Hämophilie in Deutschland, Österreich und der Schweiz. Hämostaseologie, 28(Suppl1), pp. 29-30. Stuttgart: Schattauer
